Literature DB >> 29619961

Genomics Reloaded: Rise of the Expression Profiles.

Gregory N Gan, Randall J Kimple.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29619961      PMCID： PMC6821516          DOI： 10.1016/j.ijrobp.2017.10.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  17 in total

1.  Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.

Authors:  Adam D Swick; Prashanth J Prabakaran; Margot C Miller; Amal M Javaid; Michael M Fisher; Emmanuel Sampene; Irene M Ong; Rong Hu; Mari Iida; Kwangok P Nickel; Justine Y Bruce; Deric L Wheeler; Randall J Kimple
Journal:  Mol Cancer Ther       Date:  2017-04-26       Impact factor: 6.261

2.  Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.

Authors:  Paolo Bossi; Cristiana Bergamini; Marco Siano; Maria Cossu Rocca; Andrea P Sponghini; Federica Favales; Marco Giannoccaro; Edoardo Marchesi; Barbara Cortelazzi; Federica Perrone; Silvana Pilotti; Laura D Locati; Lisa Licitra; Silvana Canevari; Loris De Cecco
Journal:  Clin Cancer Res       Date:  2016-02-26       Impact factor: 12.531

3.  Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

Authors:  Nishant Agrawal; Mitchell J Frederick; Curtis R Pickering; Chetan Bettegowda; Kyle Chang; Ryan J Li; Carole Fakhry; Tong-Xin Xie; Jiexin Zhang; Jing Wang; Nianxiang Zhang; Adel K El-Naggar; Samar A Jasser; John N Weinstein; Lisa Treviño; Jennifer A Drummond; Donna M Muzny; Yuanqing Wu; Laura D Wood; Ralph H Hruban; William H Westra; Wayne M Koch; Joseph A Califano; Richard A Gibbs; David Sidransky; Bert Vogelstein; Victor E Velculescu; Nickolas Papadopoulos; David A Wheeler; Kenneth W Kinzler; Jeffrey N Myers
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

4.  The mutational landscape of head and neck squamous cell carcinoma.

Authors:  Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.

Authors:  Konrad Klinghammer; Raik Otto; Jan-Dirk Raguse; Andreas E Albers; Ingeborg Tinhofer; Iduna Fichtner; Ulf Leser; Ulrich Keilholz; Jens Hoffmann
Journal:  Int J Cancer       Date:  2017-06-21       Impact factor: 7.396

6.  Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.

Authors:  Randall J Kimple; Paul M Harari; Alexandra D Torres; Robert Z Yang; Benjamin J Soriano; Menggang Yu; Eric A Armstrong; Grace C Blitzer; Molly A Smith; Laurel D Lorenz; Denis Lee; David T Yang; Timothy M McCulloch; Gregory K Hartig; Paul F Lambert
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

7.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.

Authors:  Stephen B Keysar; David P Astling; Ryan T Anderson; Brian W Vogler; Daniel W Bowles; J Jason Morton; Jeramiah J Paylor; Magdalena J Glogowska; Phuong N Le; Justin R Eagles-Soukup; Severine L Kako; Sarah M Takimoto; Daniel B Sehrt; Adrian Umpierrez; Morgan A Pittman; Sarah M Macfadden; Ryan M Helber; Scott Peterson; Diana F Hausman; Sherif Said; Ted H Leem; Julie A Goddard; John J Arcaroli; Wells A Messersmith; William A Robinson; Fred R Hirsch; Marileila Varella-Garcia; David Raben; Xiao-Jing Wang; John I Song; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Oncol       Date:  2013-04-04       Impact factor: 6.603

8.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.

Authors:  Loris De Cecco; Monica Nicolau; Marco Giannoccaro; Maria Grazia Daidone; Paolo Bossi; Laura Locati; Lisa Licitra; Silvana Canevari
Journal:  Oncotarget       Date:  2015-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.